Chronic Hives (Urticaria) — VA Disability Rating Criteria (DC 7825)

Diagnostic Code 7825 · 38 CFR §4.118

What Is It?

Urticaria is hives: raised, intensely itchy welts that swell up, migrate around the body, and usually fade within a day only to appear somewhere else. About half of people with chronic hives also get angioedema, the deeper swelling of lips, eyelids, hands, feet or throat that can be frightening and occasionally dangerous. DC 7825 does not rate ordinary short-lived hives — it rates CHRONIC urticaria, and the diagnostic code carries its own definition of that word: continuous urticaria at least twice per week, off treatment, for a period of six weeks or more. In most cases no trigger is ever identified, which is why the medical name for the common form is chronic spontaneous or chronic idiopathic urticaria; the absence of a known cause does not affect the rating. Veterans reach it through documented reactions to medications, vaccines, insect stings and chemical exposures, through autoimmune disease, and through the physical urticarias in which pressure, cold, heat, vibration or exercise brings out the welts. The one thing to understand before filing is how the code measures severity. It does not count outbreaks. The VA rewrote the skin schedule effective 13 August 2018 and replaced the old episode-frequency criteria with a treatment ladder: the rating is set by which line of treatment it takes to control your hives, and whether that treatment works.

Rating Criteria

Evidence Needed

Two things carry this claim, and neither of them is a photograph of a bad week. The first is the diagnosis of CHRONIC urticaria as the code defines it: continuous hives at least twice per week, off treatment, for six weeks or more. Get that phrase, or its clinical equivalent, written into an allergy, immunology or dermatology note, because a record that says only "urticaria" invites the rater to treat it as an acute episode. The second is the treatment ladder, and it is proved by pharmacy records more than by narrative. What the rating turns on is which line of therapy your hives need and whether it controls them: antihistamines alone is 10 percent; corticosteroids, leukotriene inhibitors such as montelukast, sympathomimetics, neutrophil inhibitors such as dapsone or colchicine, or thyroid hormone is 30 percent; and third line therapy — omalizumab and other immunotherapy, cyclosporine and other immunosuppressives, or plasmapheresis — after first and second line failed is 60 percent. So the file wants the full medication history in order, with dates, doses, and the clinician's reason for each escalation, plus the notes recording that the previous line did not control the condition. Add the specialist referral itself, any UAS7 or urticaria activity scoring your clinic uses, allergy and autoimmune workup results, angioedema documentation and any emergency treatment for airway involvement, and a nexus opinion where the hives began after a documented in-service exposure, medication or vaccination.

C&P Exam Tips

Bring the medication list, in chronological order, and treat it as the centerpiece of the examination rather than a footnote — under the current criteria it IS the rating. For each drug, be ready to say when it started, why it was added, and whether it worked; the criteria are written around the failure of one line and the escalation to the next, so "we tried cetirizine and fexofenadine at double dose and they did not control it, so I was started on montelukast" is the kind of sentence that decides the level. Say the word refractory if it is accurate and a clinician has used it. Bring dated photographs of outbreaks, since hives frequently vanish for the appointment, but understand that photographs support the diagnosis rather than set the level. Describe angioedema separately if you get it — lip, eyelid, tongue or throat swelling, and any emergency visit or epinephrine use — because it is the part of the picture most likely to be omitted and the part that most affects daily risk. Describe the sleep loss and the effect of sedating antihistamines on work and driving. And correct the examiner gently if the questioning turns on how many outbreaks you have had in the past year: episode counting was the pre-2018 standard and it is not what the current code asks.

How to File

File under DC 7825, and name the in-service event where there is one — the medication, the vaccination, the insect envenomation, the chemical or environmental exposure, or the onset date if the hives began in service and never resolved. Attach the specialist records establishing chronic urticaria as the code defines it, the complete medication history with dates showing the escalation from one treatment line to the next, and the notes recording that the earlier line failed. Where the hives are a side effect of medication taken for another service-connected condition, or are associated with a service-connected autoimmune or thyroid disorder, file as secondary and include a nexus opinion naming the pathway. If you also get angioedema with airway involvement, document every emergency presentation. And if your existing rating was assigned under the pre-2018 episode-frequency criteria and your treatment has since escalated to a higher line, that escalation is the basis for a claim for increase under the current criteria.

Common Mistakes

The biggest mistake in 2026 is arguing the wrong criteria — and this is a case where a veteran can do everything else right and still be rated on a standard that no longer exists. The pre-2018 DC 7825 counted debilitating episodes in the past 12 months, and that language still fills older guides, older decisions and the memory of anyone who filed before August 2018. The current code asks only which line of treatment is required for control. A veteran who spends the claim documenting outbreak counts, and never assembles the medication history, has built evidence for a superseded rule. The second mistake follows from the first: not escalating care. Hives controlled on antihistamines are 10 percent, and that is the correct rating for hives controlled on antihistamines — but if over-the-counter antihistamines are NOT controlling yours, staying on them means both worse symptoms and a lower rating than the condition warrants. Seeing an allergist and getting the next line prescribed is the medically right move and it is what the criteria measure. The third is losing the pharmacy record, which is the single most probative document and the easiest to obtain. The fourth is leaving angioedema and its emergency treatment out of the file. The fifth is assuming an idiopathic diagnosis is a problem: most chronic urticaria has no identified trigger, and the code does not require one.

Frequently Asked Questions

Did the VA change how it rates chronic hives?

Yes, and the change is fundamental. The skin schedule at 38 CFR 4.118 was rewritten by a final rule effective 13 August 2018. The old DC 7825 rated on how many debilitating episodes you had in the past 12 months and whether you needed intermittent or continuous immunosuppressive therapy. The current code deleted episode counting entirely and rates on the treatment line required for control: antihistamines is 10 percent, second line therapy is 30 percent, and refractory disease requiring third line therapy is 60 percent. If a decision on your claim counts outbreaks, it is applying superseded criteria.

What does the VA mean by chronic urticaria?

DC 7825 defines it inside the code: continuous urticaria at least twice per week, off treatment, for a period of six weeks or more. The words "off treatment" matter — the six-week baseline describes the untreated condition, not what happens once you are on medication. This is why the diagnosis needs to be stated in those terms in your records. Hives that resolve within six weeks are acute urticaria and are not what this code compensates.

What counts as first, second and third line treatment?

The code gives examples for each. First line is antihistamines. Second line is listed as corticosteroids, sympathomimetics, leukotriene inhibitors, neutrophil inhibitors, or thyroid hormone — so montelukast, prednisone, dapsone and colchicine are the drugs most often seen at this level. Third line is listed as plasmapheresis, immunotherapy, or immunosuppressives, which in current practice usually means omalizumab or cyclosporine. The lists are examples rather than closed sets, so what matters is where your clinician places the drug in the treatment sequence and why it was needed.

Do I need to know what causes my hives?

No. Chronic spontaneous urticaria — hives with no identifiable trigger — is the most common form of the condition and is fully ratable. DC 7825 rates the condition and the treatment it requires, not the presence of an identified allergen. What service connection requires is a link between service and the onset or aggravation of the condition, which can rest on documented in-service onset, on a specific exposure, or on a secondary pathway from another service-connected disability, and none of those depends on naming the trigger.

Can I get more than 60 percent for hives?

Not under DC 7825 — 60 percent is the top of the code. What can be evaluated alongside it is a genuinely separate manifestation: angioedema with airway involvement documented as its own condition, an underlying autoimmune or thyroid disorder rated under its own code, or a secondary mental-health disability from the sleep loss and unpredictability, which is a well-recognized route. 38 CFR 4.14 bars rating the same manifestation twice, so the case for anything additional has to rest on symptoms the urticaria evaluation does not already account for.

My hives are controlled now. Will my rating be reduced?

A rating can be reduced when the evidence shows sustained improvement, and here that would mean stepping back down the treatment ladder — a veteran on omalizumab who returns to antihistamines alone is describing improvement in exactly the terms the code measures. Two protections apply. A reduction requires the VA to follow 38 CFR 3.105(e): notice of the proposal, 60 days to submit evidence, 30 days to request a predetermination hearing, and a separate decision. And 38 CFR 3.344 requires that improvement be sustained under the ordinary conditions of life rather than shown on a single examination. Control achieved BY continuing a higher line of treatment is not improvement — it is the criterion being met.